Alan Sandler, M.D. serves as the Chief Development Officer at Revolution Medicines, leading the company’s global Development organization, including clinical sciences, global patient safety, clinical operations, regulatory, quality, development strategy and operations, quantitative sciences, translational medicine, nonclinical development and clinical pharmacology.
Alan brings internationally recognized expertise in oncology drug development and clinical research, built on a distinguished career as both an academic lung cancer oncologist and industry leader in global drug development, and has contributed to several successful drug approvals.
Most recently Alan served as Chief Medical Officer of ALX Oncology, where he led clinical strategy and advanced the company’s immune-oncology pipeline. Before ALX, he was Chief Medical Officer of Mirati Therapeutics, Inc. through Mirati’s acquisition by Bristol Myers Squibb. Previously, he served as President and Head of Global Development, Oncology at Zai Lab Limited, and earlier held senior leadership roles at Genentech, a member of the Roche Group, where he drove multiple oncology development programs. Alan has also held academic leadership roles at Oregon Health and Science University, Indiana University and Vanderbilt University.
Alan earned his M.D. from Rush Medical College and completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center.
What is Alan B. Sandler's net worth?
The estimated net worth of Alan B. Sandler is at least $10.50 million as of September 29th, 2026. Dr. Sandler owns 52,559 shares of Revolution Medicines stock worth more than $10,496,032 as of November 4th. This net worth evaluation does not reflect any other investments that Dr. Sandler may own. Learn More about Alan B. Sandler's net worth.
How do I contact Alan B. Sandler?
Has Alan B. Sandler been buying or selling shares of Revolution Medicines?
Alan B. Sandler has not been actively trading shares of Revolution Medicines within the last three months. Most recently, Alan B. Sandler sold 6,309 shares of the business's stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $202.14, for a transaction totalling $1,275,301.26. Following the completion of the sale, the insider now directly owns 52,559 shares of the company's stock, valued at $10,624,276.26. Learn More on Alan B. Sandler's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Elizabeth Anderson (Director), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Alan Sandler (Chief Development Officer), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), Barbara Weber (Director), and Lin Wei (Chief Medical Officer). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, insiders at the sold shares 37 times. They sold a total of 851,872 shares worth more than $125,150,523.18. The most recent insider tranaction occured on September, 29th when insider
Alan B. Sandler sold 6,309 shares worth more than $1,275,301.26. Insiders at Revolution Medicines own 7.6% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 9/29/2026.
